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Greater understanding of programmed cell death (PCD) responses in pathogenic fungi may offer a chance of exploiting the fungal molecular
death machinery to control fungal infections. Clearly identifiable differences between the death machineries of pathogens and their hosts, make
this a feasible target. Evidence for PCD in a range of pathogenic fungi is discussed alongside an evaluation of the capacity of existing antifungal
agents to promote apoptosis and other forms of cell death. Information about death related signalling pathways that have been examined in
pathogens as diverse as Candida albicans, Aspergillus fumigatus, Magnaporthe grisea and Colletotrichum trifolii are discussed.
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Programmed cell death appears to be a ubiquitous feature of
living systems, and has been described in one form or another in
the majority of phylogenetic lineages including eubacteria,
protists, plants and animals [1–8]. The wide spread occurrence
of PCD hints either at an ancient origin, or suggests that it is an
aspect of the life of both unicellular and multicellular organisms
which has evolved many times over. In either case, PCD plays
an important part in the life-histories of most organisms
including fungi [9,10].
Differences in the nature of death responses are often a
reflection of basic differences in the cell biology of the organisms
under consideration. It is now apparent however that at a deep-
rooted level, related molecules are taking part in the cell death
decisions of organisms as diverse as bacteria, yeast, plants,
worms, flies and man. Much research has focused on this simi-
larity, but when differences are found they should be celebrated,
as they may, in the case of pathogenic organisms provide a new
avenue of investigation that could be exploited in the design of
drugs that fight infectious diseases of plants and animals.
The core features of the PCD responses in mammals are
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suicide programmes. In the intrinsic death pathway, death sig-
nals induce the release of mitochondrial proteins [11–13] re-
sulting in an amplification of a caspase cascade [11,14,15]. In the
extrinsic pathway, signals mediated by death receptors of the
TNF receptor superfamily activate the caspase cascade directly.
Caspase independent suicide pathways may also be initiated in
response to stress (eg after exposure of cells to ROS) that involve
the translocation of an apoptosis inducing factor (AIF) from the
mitochondrion to the nucleus.
PCD is commonly associated with the fragmentation of nuclei
and degradation of DNAwhich can be linked to the activity of a
number of different nucleases [16–23]. PCD is also accompanied
by a loss of phospholipid asymmetry that involves the translo-
cation of phosphatidylserine (PS) to the outer leaflet of the plasma
membrane [24,25]. Such lipid bilayer rearrangements require the
activation of non-specific bidirectional phospholipid flippases
and floppases along with the inhibition of aminophospholipid
translocases, or scramblases that normally recycle PS to the
inner leaflet [26,27]. ATP-binding cassette transporters such as
ABCA-1 and CED-7 have been implicated in transbilayer redis-
tribution of PS [28]; perhaps of some significance therefore is the
finding that homologues of such ABC-transporter enzymes in
fungi have been implicated in antifungal drug resistance [29–31]
though their roles in fungal cell death per se have yet to be
explored.
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Programmed cell death responses have now been described in
a range of fungi [9,10] though the majority of studies are focused
on the yeasts Saccharomyces cerevisiae, Schizosaccharomyces
pombe and Candida albicans [32–37]. Fungal cells dying under
a range of conditions exhibit several markers characteristic of
apoptosis, including the rapid exposure of PS at the outer cell
membrane (revealed by annexin binding), the margination of
chromatin in nuclei, nuclear fragmentation and the degradation
of DNA (revealed by the TUNEL test). In many cases it has been
shown that exposure of cells to cycloheximide prevents these
death associated changes, indicating that the death response
requires active protein synthesis (eg [38]).
Functional analyses of genes in yeast have revealed that there
are some similarities at the molecular level between fungal
apoptosis and apoptosis of higher eukaryotes, with the iden-
tification of homologues of caspase-like cysteine proteases [39],
AIF [40] and Htr2A/Omi [41]. On the whole it is anticipated
that the proteins responsible for fungal cell death will be suf-
ficiently distinct from their mammalian counterparts to make
drug therapies feasible since bioinformatic screens of fungal
genomes have shown that many of the known components of
higher organism apoptosis are missing or highly divergent at
the amino acid level [42]. The discovery of PCD responses in
the model pathogenic fungi C. albicans [36,37], Aspergillus
fumigatus [43,44] andMagnaporthe grisea [45] raises the long-
term possibility of developing novel antifungal drugs and fun-
gicides that clear infections by activating fungal cell suicide.
Identification of the endogenous molecular switches that trigger
fungal apoptosis is of paramount importance if we are to achieve
these aims.
3. Fungal pathogens of man, animals and plants
Fungi can affect human welfare by destroying crop plants [46]
or by causing life-threatening diseases in immuno-compromised
individuals [47]— see Table 1 for a summary of the pathogenic
fungal species considered in this review and the literature
considered.
In humans the major threats to our health are posed by
pleiomorphic fungi, ie those that can grow in yeast, pseudohyphal
or filamentous growth forms. Most notable amongst the
pleiomorphic fungal pathogens is C. albicans and its close rela-
tives (C. dubliniensis,C. krusei,C. parapsilosis,C. tropicalis), as
well as the more distant relative, Candida glabrata. The other
major human pathogenic fungi that cause life-threatening disease
are A. fumigatus, Cryptococcus neoformans, Histoplasma
capsulatum, Coccidioides immitis, Paracoccidioides brasiliensis
and Blastomyces dermatidis. A number of additional human
pathogens are now also emerging as significant threats to specific
patient groups (particularly HIV-positive patients) including Pe-
nicillium marneffei [48] and Pneumocystis jiroveci, formerly
known as P. carinii [49]. In addition to these pathogens, a large
number of clinically important dermatophyte fungi (numbering in
excess of 600) can cause both irritating and/or disfiguring super-
ficial infections. Amongst these,Malassezia globosa, a yeast thatcauses dandruff, as well as more severe seborrheic dermatitis,
affects more than 50% of the human population and may contrib-
ute to atopic eczema in sensitized patients [50,51]. Trichophyton
rubrum and T. mentagrophytes, cause superficial skin infections
most notably athlete's foot, and are considered to be the second
most common cause of skin infections after acne [52].
C. albicans has become a molecular genetics work-horse for
the study of pathogenicity, virulence and fungal development
[53]. Candida species are typically commensal organisms,
present on about 50% of the population at any one time [54].
Over a lifetime however, some 80% of women suffer from
clinical Candida infections, and about 5% of these thrush in-
fections can be recurrent, with some infections becoming
resistant to antifungal therapy. In immuno-compromised indi-
viduals, C. albicans can produce mild but irritating, superficial
infections of the oral and vaginal mucosa. In severely immuno-
compromised patients, C. albicans can produce a disseminated
systemic infection which if not treated effectively is associated
with a high incidence of mortality. Systemic C. albicans in-
fections typically occur in patients undergoing chemotherapy
or organ transplantation and, depending upon the patient group,
one-third to one-half of these infections are fatal. The incidence
of infection amongst premature and small babies can be as high
as 7%, and over half of these patients may not survive [55].
C. albicans is also the fourth most common hospital acquired
infection and typically extends a patient's stay in the hospital by
an average of 30 days. The number of clinical C. albicans
infections in UK hospitals has risen significantly in recent years
[56], and the incidence of resistance to traditional antifungal
therapies is high [57]. Candida infections are therefore both
socially and economically devastating.
4. Major plant pathogenic fungi
Human pathogenic fungi that cause life-threatening disease
represent a small fraction of the species that cause disease.
Indeed, whilst the majority of fungi are benign, a large number
produce diseases in plants affecting crop yields and profit
margins which can have serious consequences on both local and
global scales.
Arable food production worldwide is mainly based upon
four staple crops — rice, wheat, maize and potato [58]. All of
these are subject to infection by a significant number of plant
pathogenic fungi. Fungicides are vital for the control of plant
diseases, which are estimated to cause yield reductions of
almost 20% in the major food and cash crops worldwide [59].
Arguably at the top of the list of plant pathogenic fungi is the
filamentous ascomycete M. grisea (sexual state Pyricularia
oryzae), the causative agent of Rice Blast Disease [46]. Annually,
Rice Blast is responsible for a loss of between 10 and 30% of the
rice harvest. Other plant pathogens that pose serious environ-
mental and socioeconomic threats include Tilletia indica (Karnal
Bunt, [60]) and Pucciniania kuehnii (Sugar Cane Orange Rust
[61]). Cryphonectria parasitica a basidiomycete pathogen
causing Chestnut Blight [62,63] and Ophiostoma spp another
ascomycete (Dutch Elm Disease [64]) have also caused major
losses in forestry in recent years.
Table 1
Fungal pathogens and their control
Organism Disease Front line antifungals a PCD reported b General information c
Aspergillus fumigatus Aspergillosis AmB, ITZ, VOR [43,44,99] [31,75,89,99,112,113,132]
Blastomyces dermatidis Blastomycosis, Gilchrist's Disease AmB, ITZ
Candida albicans and
other Candida spp.
Candidiasis, Thrush AmB, ECH, FCZ, NYS [36,37,98,102,103,109,
121,151,172]
[29,30,53–57,76,80–82,
84–86,89,91,96–98,103,110,111,131,
145,146,147,166,168,169,170,171]
Coccidioides immitis Coccidioidomycosis, San Joaquim
Valley Fever
AmB, FCZ
Colletotrichum gloeosporioides Anthracnose BEN, PCZ, TBA [115]
Colletotrichum trifolii Alfalfa Anthracnose BEN, PCZ, TBA [120]
Cryphonectria parasitica Chestnut Blight Non registered [117,118] [62,63,119]
Cryptococcus neoformans Cryptococcosis AmB, FCZ, FLU [114]
Histoplasma capsulatum Histoplasmosis, Darling's Disease AmB, ITZ, [114]
Magnaporthe grisea Rice Blast PBA, PHT, PYQ, TCA [45] [46,94,95,141,142]
Malassezia globosa Dandruff, Seborrhoeic Dermatitis KET, TBF [50,51]
Ophiostoma spp Dutch Elm Disease PCA, TBA [64]
Paracoccidioides brasiliensis Paracoccidiomyccosis,
Lutz–Splendore–Almeida disease
AmB, ITZ
Penicillium marneffei PM Infection AmB, ITZ [48]
Phytophthora cinnamomi Jarrah Die-Back MET, PPA [73]
Phytophthora infestans Potato Late Blight MET [66–71]
Phytophthora ramorum Sudden Oak Death Syndrome CZF, DMM [72]
Pneumocystis jiroveci (carinii) Pneumocystis Pneumonia (PCP) SMA, TRI [49]
Pucciniana kuehnii Sugar Cane Orange Rust PPA, Sulphur [61,65]
Stachybotrys chartarum Black Mould Allergy Non registered [74]
Tilletia indica Karnal Bunt PCA [60]
Trichophyton mentagrophytes Athletes Foot, Tinea CPO, ITZ, TBF [52]
Trichophyton rubrum Athletes Foot, Tinea CPO, ITZ, TBF [52]
a AmB (amphotericin), BEN (benomyl), CPO (cyclopirox olamine), CZF (cyazofamid), DMM (dimethomorph), ECH (echinocandin), FCZ (fluconazole), FLU
(Flucytosine), ITZ (itraconazole), KET (ketoconazole), MET (metalaxyl), NYS (nystatin), PBA (probenazole), PCA (propiconazole), PCZ (prochloraz), PHT (phthalide),
PPA (potassium phosphonate), PYQ (pyroquilon), SMA (sulphamethoxazole), TBA (thiabendazole), TCA (tricyclazole), TRI (trimethorprim), and VOR (voriconazole).
b References in main text referring to PCD responses.
c References in main text referring to disease or therapy.
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(second only to viral infectious diseases at 47%) [65]. Despite
extensive breeding programmes for resistance to fungal patho-
gens, the shear numbers of fungal propagules in the environ-
ment and the ability of fungi to generate diversity through sexual
and parasexual recombination often mean that control is limited
to only a few seasons before new virulent strains arise.
Amongst the oomycetes, Phytophthora infestans (Potato
Late Blight) is still themost important threat to potato production
worldwide [66]. This pathogen which coevolved with wild
potato (Solanum) species was transported to Mexico from South
America [67] from where it spread to cultivated crops world-
wide. It was introduced into the USA in about 1840 and was
subsequently transported to Europe where it decimated potato
production, causing the Irish potato famine and the forced
migration of five million people [68]. Blight was re-introduced
from Mexico into the USA and Canada during the early 1990s
[69,70] and outbreaks of blight continue to this day, causing
devastating local and global epidemics potentiated by the
emergence of virulent fungicide-resistant strains such as US-8
[71]. Other species of Phytophthora are the cause of major
economic and environmental losses including P. ramorum in
Europe (Sudden Oak death Syndrome [72] and P. cinnamomi in
Australia (Jarrah Die-Back [73]).5. Fungi as pests/spoilage organisms
Fungi also affect our quality of life more indirectly by
damaging/spoiling food-stuffs (which leads to both economic
losses or the production of food-stuffs contaminated with
health-threatening mycotoxins). Fungi can colonize our homes,
workplaces and hospitals (damaging property) and following
the production of copious quantities of airborne spora, induce
allergic reactions that can in some case be life-threatening eg
Stachybotrys chartarum [74] and A. fumigatus [75]. Reducing
the economic and environmental threats posed by such con-
tamination requires the treatment of foods or property with a
range of preservative agents that that can become less effective
with prolonged use, and themselves may be considered harmful
to our health or the environment.
6. Worldwide economic losses attributed to fungal disease
In 2006 the annual fungicide market aimed at arable crops
was estimated to be $7.2 billion [173]. Such massive expen-
diture is however offset by the economic gains arising from the
increase in yields/productivity which are thought to have netted
the farming industry $12 billion dollars in additional revenue.
At a local level the impact of losing a crop can however be
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Currently the antifungal drug market is of comparable size,
estimated to be about $11.9 billion in 2007 [174].
7. Current practice— antifungals and fungicides
The design and implementation of effective antifungal/
fungicide therapies is complicated by basic similarities in the
cellular organization of pathogenic fungi and their hosts. In a
medical setting many antifungal drugs are quite toxic to patients;
precluding their long-term use.
Current antifungal treatments used in healthcare largely target
essential processes at the fungal cell surface, such as plasma
membrane or cell wall biogenesis. Several distinct classes of
antifungal drugs are currently available for the treatment of
clinical fungal infections. Novel antifungals are always under
development, but the mainstays of treatment and the most widely
used are azoles, polyenes, allylamines, 5-fluorocytosine (5FC)
and the echinocandins [76].
The polyene antifungal amphotericin B (AmB) has been used
clinically for over 30 years [77]. FormulatingAmBwith liposomes
[78] and lipid complexes [79] has allowed the use of higher doses
of AmB, which can be useful in the treatment of recalcitrant
infections. The primary mode of action of AmB, in common with
other polyene antifungals is thought to arise from its affinity for
ergosterol. Integration of AmB into the cell membrane results in
the formation of aqueous pores, which leads to altered plasma
membrane permeability which is subsequently accompanied by
loss of mono- and divalent cations leading to cell death [80]. The
minimal inhibitory concentrations (MIC90) of AmB for a variety of
species of Candida range from 0.25 to 1 µg/ml [81], whilst the
minimal fungicidal concentrations (MFC) may be up to 2 fold
higher. The fungicidal action of AmB makes it useful in the treat-
ment of systemic candidiasis, Candida meningitis and ophthal-
mitis [76] as well as infections that are traditionally regarded as
resistant to azoles egC. krusei andC. glabrata. Polyenes also have
a strong affinity for host sterols, especially cholesterol [82], which
is associated with a number of side-effects, most importantly renal
toxicity precluding their use in long-term therapy [83]. Resistance
to AmB can be intrinsic, with isolates of Candida luscitaniae
commonly failing to respond [76]. Acquired resistance, though
rare, has been described, and is linked to the selection of mutants
that accumulate 3β-ergosta-7,22-dienol and 3β-ergosta-8-dienol,
which is associated with a defect in sterol Δ5,6 desaturases
[84,85]. Increased catalase activity has also been found to offset the
oxidative (ROS) damage that accompanies AmB treatment
of fungal cells which is thought to contribute to its fungicidal
properties [86].
Azoles were discovered in the 1960s and have been the main-
stay of antifungal therapies for a number of years. Two classes of
azole antifungal drug have been developed, N-1 substituted imid-
azoles (eg ketoconazole, clotrimizole) and triazoles (eg flucona-
zole, itraconazole). Azoles target the CYP51A1 cytochrome P450
required for the 14α-demethylation of lanosterol [87] and the
Δ22-desaturase involved with the desaturation of ergosta-5,7-
dienol [88]. Nitrogen in the imidazole or triazole rings bind to
the haem iron of cytochrome P450, inhibiting its action. Theinteraction depends on the precise conformation of the enzyme,
thereby affecting the range of species against which individual
azoles are effective. Despite this, azoles do generally possess
broad-spectrum antifungal properties and are used in the treat-
ment of Candida spp., Cryptococcal infections, H. capsulatum,
C. immitis and dermatophytes. The incidence of resistance to
front-line azole antifungals is however one of the major driving
forces behind the need to develop new active agents.
Exposure of fungi to 5-Fluorocytosine (5FC) leads to its uptake
by cytosine permeases. Once inside a cell, 5FC is deaminated to
5FU and then converted to a nucleoside triphosphate, which when
incorporated into RNA causes miscoding. 5FU, itself is also
converted to a deoxynucleoside, which can subsequently inhibit
thymidylate synthase. 5FC is fungicidal, however its spectrum of
activity is limited because of widespread resistance, which is
greatest amongst Aspergillus and Candida species [89]. 5-FC is
often used in combination therapy with AmB because of the rapid
acquisition of resistance by treated infections. Combined thera-
pies often show contradictory responses in vitro, but in vivo
animal models of both candidiasis and cryptococcosis do gener-
ally respond well [90].
Allylamines were initially developed in the 1970s and in-
clude terbinafine, naftidine and structurally related compounds
such as tolnaftate. The allylamines inhibit squalene epoxidase, the
first enzyme in the committed stage of ergosterol biosynthesis.
Allylamines function as reversible, non-competitive inhibitors of
squalene epoxidase which leads to ergosterol depletion.
Terbinafine is fungicidal against filamentous dermatophytes,
but is only fungistatic against Candida species. Co-treatment of
cells with calcineurin inhibitors eg cyclosporin A or FK506 can
alter this balance promoting cell death, potentially expanding
the utility of this drug [91].
Echinocandins, a class of cyclic lipohexapeptides are the most
recent additions to the arsenal of antifungal drugs. Echinocandins
have been shown to act as non-competitive inhibitors of β-1,3
glucan synthase which is required for the synthesis of glucan
polymers, a major component of the fungal cell wall. Caspo-
fungin, the first commercially available form of echinocandin,
displays fungicidal activity against Candida, Aspergillus, Histo-
plasma, Coccidioides and Blastomyces, however it lacks activity
against Cryptococcus and many filamentous fungal pathogens.
Micafungin is fungicidal against yeasts [92], but only shows
fungistatic properties against aspergilli. Currently there are no
reports of resistance developing against these drugs in a clinical
setting.
Fungicides used in the treatment of plant disease are very
diverse, targeted at both narrow and wide spectra of fungal
pathogens. Sulphur containing compounds and strobilurins inhibit
the electron transport chain, the latter blocking ubiquinol-cyto-
chrome c oxidoreductase of the cytochrome bc1 complex III [93].
Copper fungicides, dithiocarbamates, substituted aromatics and
organophosphorous compounds inhibit the activities of a wide
range of enzymes and are relatively non-selective. Ben-
zimidazoles and phenylamides inhibit DNA and RNA synthesis
respectively, whilst dicarboximides inhibit both. Cyclopropane
carboxamide carpropramid and phenoxyamide (AC382042) both
target scytalone dehydratase and therefore inhibit the synthesis of
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agriculture — potentially with the risk of the development of
resistance to such agents amongst clinical isolates.
8. Resistance to antifungals
Resistance of pathogenic fungi to traditional antifungal thera-
pies is a perennial problem and in some clinical situations is
alarmingly high [57]making the identification of novel targets for
antifungal therapy of some urgency. Resistance to antifungal
drugs has both clinical and microbiological components [76].
Successful therapy depends upon a number of factors that not only
depend upon the activity of the antifungal therapy but also the
pharmacokinetics of the drug in a patient, and the status of their
immune system. Resistance can arise through inefficient/
inappropriate dosing of patients, inappropriate selection of
antifungals, or repeated exposure. In recent years there has been
a significant shift towards the isolation of more resistant Candida
species in hospitals such as C. glabrata. The administration of
azole antifungals as a prophylactic treatment may be a significant
contributor to this trend [96,97].
Ideally microbiological resistance will be predictive of clinical
resistance, though this is often not the case. Some fungi are
intrinsically resistant to specific classes of antifungal drug
eg, fluconazole is highly efficacious against C. albicans and
C. parapsilosis, but C. glabrata and C. krusei are less susceptible
[76].
Low mammalian toxicity and environmental impact as well
as low residues in food, and compatibility with integrated pest
management programmes are very important features that are
required of new antifungals. A balance between cost, potency and
safety is a major goal for both the agrochemical and pharma-
ceutical industries developing new antifungal agents.
9. Examples of PCD induced in pathogenic fungi by
antifungal agents
Liao et al. [98] examined physiological changes inC. albicans
cells treated with AmB and described three patterns of death.
Death was always accompanied by a drop in ATP level but
could be subdivided on the basis of plasma membrane integ-
rity and mitochondrial membrane potential. Later, Phillips
et al. [36] found that AmB treated cells that were able to
exclude propidium iodide and produced ROS corresponded to
an apoptotic sub-population. Normal treatment of systemic
candidiasis may therefore already reduce infection loads by
initiating apoptosis.
Protoplasts of A. fumigatus treated with 0.25–1 µg ml−1 AmB
stain positive with annexin V, indicating PS translocation to the
outer surface of the plasma membrane and also display dsDNA
breakage, detectable with the TUNEL assay [99]. Propidium
iodide staining (indicative of necrosis) is less than 20% at 0.25 and
0.5 µg ml−1 AmB, but increases to 85% at higher doses. Pre-
incubation of cells with cycloheximide prevents the appearance of
apoptotic markers, indicating that killing requires active transla-
tion. In contrast, cycloheximide is not able to prevent the for-
mation of propidium iodide positive cells at 1 µg ml−1. Takentogether this suggests that at low fungicidal doses, AmB is pro-
apoptotic and at higher doses it is pro-necrotic.
Pradimicin A, a broad-spectrum fungicidal antifungal agent
which binds to mannan residues in the cell wall [100], also
induces apoptosis-like cell death in S. cerevisiae [101]. Nuclear
fragmentation and DNA damage have been observed in yeast
cells treated with Pradimicin A, accompanied by an accumula-
tion of reactive oxygen species (ROS). Pradimicin-induced cell
death and the accumulation of ROS are prevented by free
radical scavengers, suggesting some dependency between the
two.
Translational inhibitors such as the phenanthrolines have
been shown to kill both mammalian and C. albicans cells [102].
Mammalian cells exposed to phenanthrolines show hallmarks of
apoptosis, whilst C. albicans cells accumulate ROS and display
elevated oxygen consumption rates. Nuclear disruption, including
enlargement and formation of crescent shaped bodies, has been
observed after treatment of yeast cells with some (though not all)
silver, copper and manganese metal ‘phen’ complexes The
production of ROS in the absence of DNA damage could imply
that ROS play a primary role as a signal of apoptosis and do not
act directly as the DNA damaging agents. Killing by these
translational inhibitors may involve a reduction in the levels of
cytochromes b and c and the associated uncoupling of respiratory
function which might contribute to the formation of pro-apoptotic
ROS.McCann et al. [103] found that phenanthrolines lowered the
ratios of reduced:oxidised glutathione, consistent with a pro-
oxidant role for the effects of these drugs.
A number of natural antifungal proteins have been found to
exert their killing effect by induction of apoptosis-like cell
death. Osmotin, a member of the PR-5 family of plant defence
proteins isolated from tobacco [104]; the basic, cysteine-rich
antifungal protein PAF from Penicillium chrysogenum [105];
Dermaseptins from amphibian skins [106,107] and virally
encoded yeast killer toxins [108] all appear to induce apoptosis
in fungi. RsAFP2 an antifungal peptide isolated from Rapha-
nus sativus interacts with glucosylceramides in membranes of
fungi resulting in the production of ROS and the death of C.
albicans cells [109]. Salivary histatins, short histidine rich
peptides have also been shown to display both fungistatic and
fungicidal activity against a range of Candida species [110].
Wunder et al. [110] concluded that histatins did not induce
apoptosis in C. albicans since they could not find any evidence
of DNA laddering or the release of cytochrome c when isolated
mitochondria were treated with histatin 5. Although elevated
levels of ROS were detected following the exposure of cells to
histatin 5 or the intracellular expression of an Hst 5 construct,
the reduction in viability of SOD1/2mutants of S. cerevisiae or
SOD1mutants of C. albicans was the same as wild type strains
leading the authors to conclude that ROS production merely
accompanied the death response, rather than contributing
significantly to its fungicidal activity. The significant delay
in killing that occurs after treatment has begun and does
still suggests that histatins might induce some form of PCD
[36,111]. Indeed, whilst the results of Wunder et al. [110]
indicate that the primary mode of action of histatins is not the
release of cytochrome c frommitochondria, the failure to detect
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Some antifungal drugs in some species do however appear to
operate quite independently of apoptotic mechanisms. For
example treatment of protoplasts of A. fumigatus with itracona-
zole or A. nidulans with aureobasidin A, AmB or itraconazole
does not induce apoptosis [99,112]. Furthermore, fluconazole
toxicity has been shown to be independent of known apoptotic
mechanisms in yeast, though this was only tested in the context of
a failure of heterologously expressed Bcl-2 to inhibit killing and
death characteristics per se were not addressed [113].
Finally, radio-labelled monoclonal antibodies have been used
to treat C. neoformans and H. capsulatum infections [114]. An
examination of the susceptibility of these species to 213Bi and
188Rd indicated that whilst both species were quite resistant,
doses over 4 kGy produced apoptotic changes and killing.
10. Studies of PCD in pathogenic fungi
Direct studies of apoptosis-like cell death in pathogenic
fungi have given us some insights that are not possible when
looking at model fungi such as S. cerevisiae in isolation. For
example isolates of Colletotrichum gloeosporioides, a pathogen
of the weed Aeschynomene virginica, display enhanced long-
evity when expressing the anti-apoptotic Bcl-2 protein [115].
Cells are also protected from Bax-induced cell death, and
exhibit enhanced stress resistance — all generally consistent
with similar experiments in yeast [116]. However the isolates
also show enhanced mycelium production and conidiation, and
are hypervirulent to host plants. The endogenous apoptosis-
related cell machinery may therefore be important for regulating
morphogenetic switches, which are critical for proper responses
and adaptation of fungal pathogens to different environments
[10].
C. albicans activates a PCD response (with features rem-
iniscent of apoptosis and necrosis) in response to a variety of
environmental stimuli such as acetic acid, hydrogen peroxide as
well as AmB [36]. This fungal PCD response is characterized by
the rapid appearance of several classical apoptotic markers
observed in mammalian cells including a loss of cell viability
accompanied by the exclusion of the vital dye propidium iodide;
sustained oxygen consumption and metabolic activity during
cell death; the production of ROS in apoptotic cells (indicated by
oxidation of dihydrorhodamine); the condensation of chromatin
at the nuclear margin (visible with DAPI staining and TEM) and
the accumulation of DNA breaks (as revealed by TUNEL
positive staining). The exposure of PS on the outer surface of the
plasma membrane (as revealed by annexin-FITC labelling) has
also been observed. In late stages of cell death, cells lose their
ability to exclude propidium iodide linked with the onset of
secondary necrosis. Currently, we know very little about the
effector molecules that are associated with the onset of PCD in
pathogenic fungi. Using the power of functional genetics in
fungi it has been possible to ascertain the extent to which
individual signalling pathways are necessary, or sufficient for
PCD — taking us a step closer to the possible development of
antifungal drugs that stimulate PCD.11. PCD related signalling pathways in pathogenic fungi
Biella et al. [117] reported that the response of the chestnut
blight fungus C. parasitica to infection with a viral dsRNA
hypovirulence factor resembled PCD. Using microarrays to look
for genes that were differentially regulated following infection
with the virus, 295 sequences (out of 2200) were found with
changed abundance [118]. Using differential display, Chen et al.
[119] observed that 65% of the global changes initiated by viral
infection could be reproduced by manipulating G-protein and
cAMP signalling pathways — indirectly supporting a link
between death responses and Ras-cAMP-PKA activity in fungi.
Direct evidence ofRas-cAMP-PKA involvement in fungal cell
death responses comes from studies of a number of pathogens
including Colletotrichum trifolii (a pathogen of alfalfa) and
C. albicans. In C. trifolii, expression of a hyperactive oncogenic
fungal Ras protein (DRas) elevates the production of ROS leading
to abnormal fungal growth and apoptosis-like cell death when
grown under nutrient deprived conditions [120]. Addition of
antioxidants such as N-cysteine, diphenylene iodonium, or
proline can however rescue cells from undergoing apoptosis.
Proline was found to have a general suppressive effect as a ROS
scavenger, perhaps mediated by an increased level of catalase
activity in addition to a well characterized role as an osmolyte.
In C. albicans, mutations that block Ras-cAMP-PKA signal-
ling (ras1Δ, cdc35Δ, tpk1Δ, tpk2Δ) suppress or delay the apoptotic
response induced by weak acid exposure [121]. In contrast muta-
tions that stimulate signalling (RAS1val13 or pde2Δ) accelerate the
rate of entry of cells into apoptosis when cells are treated with low
doses of weak acid. Pharmacological stimulation of the Ras-
cAMP-PKA pathway (either with dibutyryl cAMP, caffeine, or
forskolin) enhances killing,whilst inhibition ofRaswith lovastatin
reduces apoptotic cell death. Transient increases in endogenous
cAMP occur under conditions that stimulate apoptosis, but not
stress or growth arrest indicating that there may be a separation of
the activity of the Ras-cAMP-PKA pathway under stress and
death-inducing conditions.
Studies of the response of S. cerevisiae cells treated with the
plant defencemolecule osmotin, shedmore light on this idea, since
the production of ROS, expression of antioxidant proteins and the
apoptotic response are partially dependent upon an induced sup-
pression of the RAS2/cAMP pathway [104]. RAS2G19V, a domi-
nant active allele of Sc RAS2, increases sensitivity of cells to
osmotin and a null mutant shows reduced sensitivity. The response
can be linked specifically to the Ras-PKA rather than the Ras-
MAPK signalling pathway because the effects of the dominant
active allele are also seen in a ste20 background. Consistent with
osmotin induced Ras-PKA signalling, a bcy1 null, with
constitutively active PKA activity, exhibits significantly increased
sensitivity to osmotin. De-repression of STRE-dependent tran-
scriptional responses in ras2mutants [122] might account for the
elevated resistance of RAS2 nulls to stress treatments — a view
further supported by the finding that during osmotin induced PCD,
both STRE-element and YRE-reporter constructs are repressed
[104]. It might therefore be argued that the balance between stress
and apoptotic signals determines cell fate, and that osmotin
stimulates pro-apoptotic ROS production via the activation of
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dependent) and STRE-mediated antioxidant stress response.
Over-expression of plant defence molecules induces a hyper-
branching phenotype or the formation of spiral hyphae [104] and
growth inhibition per se has long been linked to altered patterns
of hyphal branching [123,124]. Ras-signals have been linked to
morphogenesis in a number of fungi (see [125] for a review),
however a study of the link between death and morphogenesis in
C. albicans showed that it could not be attributed to any of the
known signalling pathways (EFG1, RIM101, TEC1, CPH1)
that contribute to morphogenesis [36]. Morphogenesis could
however require the integration of many signals and pathways,
including Ras under the specific conditions examined.
G-protein signals have been linked to apoptosis of A. nidulans
induced by osmotin and the antifungal protein PAF, a small basic
cysteine-rich antifungal protein produced by P. chrysogenum
[105]. PAF-treatment induces hyperpolarization of the cell mem-
brane which is accompanied by PS exposure, ROS production
and a TUNEL positive phenotype. A dominant-interferingmutant
of fadA, which leads to constitutive inactivation of heterotrimeric
G-protein signals [126] confers resistance to both osmotin [127]
and PAF [105].
Few studies of pathogenic fungi have looked at signalling
pathways other than Ras. However, several lines of evidence
suggest that Ca2+/calmodulin/calcineurin signals might affect the
fungal death response. In S. cerevisiae apoptosis induced by
pheromone treatment and salt stress have been shown to be
influenced by mutations in calmodulin/calcineurin signalling
pathway [128,129]. In addition, azole activity against S. cerevisiae
is reduced by the addition of Ca2+ and enhanced by the addition of
EGTA [130]. Inhibitors of the Ca2+ binding regulatory protein
calmodulin such as fluphenazine, calmidazolin and W-7, as well
as inhibitors of Ca2+-dependant calmodulin-regulated phospha-
tase, calcineurin (cyclosporin and FK506) enhance azole activity.
Consistent with these findings mutations that constitutively
activate calcineurin demonstrate reduced azole susceptibility.
When CRZ1 (a transcription factor regulated by calcineurin) is
disrupted cells also show enhanced azole sensitivity — clearly
indicating that the cell integrity pathway is important for the action
of these drugs.
Sanglard et al. [131] reported that FK506 treatment of
fluconazole treated C. albicans cells induced a fungicidal, rather
than a fungistatic response, which could have very important
ramifications for future drug therapy regimens. Deletion ofCYP1
prevented the fungicidal activity, implying that a cyclophilin was
essential for fluconzaole toxicity. A similar effect of FK506 has
recently been reported in A. fumigatuswhen cells are treated with
caspofungin or nikkomycin Z [132].
Using nested, iterative PSI-BLAST searches, Uren et al. [133]
identified a family of caspases, metacaspases and paracaspases in
plants, animals and fungi. In fungi several metacaspases have
been found; whilst S. cerevisiae, C. albicans, and S. pombe have
single metacaspase encoding genes (YCA1/MCA1 and PCA1
respectively), A. fumigatus, A. nidulans and N. crassa appear to
have two each [99,112,134,135]. Many studies have now shown
that apoptosis in yeast may be dependent upon the activity of the
metacaspases [39,136–138]. In some scenarios however theapoptotic killing response does appear to be metacaspase inde-
pendent [40,41,139,140].
To date experimental studies of the role of metacaspases in
the cell death response of pathogenic fungi have been limited to
A. fumigatus [43,44]. Stationary phase cultures of A. fumigatus
exhibit strong intracellular activity against substrates specific
for caspase-1 and -8 and the development of an apoptotic
phenotype is blocked by Z-FAD-fmk. However deletion of both
casA and casB, the two genes encoding the metacaspases, had
little effect on measurable caspase activity, viability of hyphae
or pathogenicity [44]. PS exposure in the double knock-out
strain was strongly abrogated, leading Richie et al. [44] to
explore other possible functions for the casA and casB genes,
including a role in endoplasmic reticulum homeostasis.
Other “non-classical” cell death pathwaysmay be linked to the
death of fungal cells and tissues. The development of turgor
pressure in appressoria in the rice blast fungus M. grisea is a
prerequisite for pathogenicity [141,142] and recently this process
has been shown to be reliant upon the autophagic death of
the germinating spore [45]. Moreover, knock-out mutants of
MgATG8 arrest conidial death, and prevent pathogenicity,
showing that the blocking of a fungal cell death response, rather
than its stimulation, can also lead to control. Blocking of fungal
PCD might also be useful is the control of many other fungi,
including the economically important rust fungi. Whilst there
have been no overt studies of PCD in rusts, it is evident that in
some situations the death of support cells in rusts is essential for
the dispersal of others [143]. Specifically terminal aeciospores are
normally separated by dead suspensor cells. Clearly prevention of
this step (blocking death) could prevent dissemination of this
important group of pathogens.
12. Genetic screens for potential antifungal drug targets
In an ongoing exploration, some 30 fungal genomes have
been fully sequenced, which currently includes 18 hemiasco-
mycetes, 8 euascomycetes and 4 basidiomycetes [144]. In total,
17 of these sequenced genomes are from fungal pathogens, with
the long-term prospect that many more will be sequenced in the
future. This enormous bioinformatic resource is now being
explored by the pharmaceutical and agrochemical industries in
the search for genes, conserved between species, that might be
useful targets for future antifungal drug therapies. Potential drug
targets are typically prioritized in terms of their degree of
essentiality, broad-spectrum potential, drug target potential,
fungal specificity, availability of functional assays, and
amenability to high-throughput screening [145].
Recognizing the need for broad-spectrum antifungals, Liu
et al. [145] identified 240 putative antifungal targets that were
conserved amongst 10 fungal species in order to develop a
system to identify target-specific inhibitors. Essentiality for a
selection of the genes was then determined in C. albicans using
a repressible CaMET3 promoter. The value of this approach is
that not only is the target known a priori, which helps with the
subsequent phase I development of the drug or fungicide, the
impact of down-regulating the gene can be directly assessed.
The use of dominant selectable markers (eg NAT1 conferring
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cline-sensitive promoters (eg the GRACE™ strain collection of
C. albicans, [146]) is particularly attractive for the validation of
the essentiality of targets prior to drug screening. Such bio-
informatic screens have yet to produce clinically useful drugs,
though the potential is clearly there [147].
Expression of pro-apoptotic members of the BCL-2 family of
proteins, Bax and Bak, have been shown to kill yeast cells, and
cell death is typically associated with an apoptotic phenotype
[148–150]. Expression of a codon-optimized BAX gene in
C. albicans has been found to result in growth inhibition and cell
death. By fusing Bax with GFP, the cell death-inducing effect of
Bax was increased due to reduced proteolytic degradation of the
Bax protein [151]. However, not all fungi respond in the same
way to heterologous pro-apoptotic proteins, with expression of
Bax in Pichia pastoris leading to growth arrest accompanied by
the condensation of chromatin, and the accumulation of
autophagic bodies [152], but no other apoptotic features.
In the search for novel antifungal drug targets we shouldn't just
restrict our search to essential genes, or to studying the effects of
the expression of heterologous pro-apoptotic proteins since the
over-expression of many endogenous genes can also lead to
growth arrest/cell death. Such genes are involved with many
different biological processes but notably include components of
the cytoskeleton [153–156] and a variety of signal transduction
pathways [157–161]. In genome wide library screens using
cDNA or genomic clones, lethal effects have been observed for
ABP1, ACT1, ARF2, ATE1, AUA1, BIK1, BNI1, BOI1, ERG6,
GCL17, HSF1, KAR1, MCM1, NHP6A, NHP6B, NPS1, NSR1,
NTH1, PRK1, PSP1, RBP1, RHO1, STE4, STE11, STE12,
SAC7, SEC17, SIR1, SNU114, SRP40, TPK1, TPK3, TUB1 and
URA2 [162–165]. Whilst the induction of PCD has not been
explicitly studies in these investigations, it is intriguing to note
that both BNI1 (Gin2) and BOI1 (Gin7) produce cells with
multiple DAPI staining bodies— perhaps hinting at evidence of
nuclear fragmentation and apoptosis [165]. Often death in an
over-expression screen will not be due to the increased activity of
a dedicated pro-death protein, but due to an imbalance in some
unrelated critical process, nevertheless, such screens could
provide a useful starting point to look for pro-death functions.
The majority of studies of essential genes, or genes that when
over-expressed prevent growth, have not so far discriminated
between the responses that are lethal and those that merely cause
growth arrest. It may therefore be of considerable value to
ascertain the degree to which shutting off/inducing gene expres-
sion induces killing, and of course by what route. Performing
screens under conditions that stimulate PCD may also allow
antagonists of PCD to be identified that have anti/pro-apoptotic
properties. Indeed, we can speculate that many of the ‘essential’
genes that have been described in fungi may have such anti-
apoptotic roles.
A final area that could be explored further in the search for
novel antifungals that stimulate fungal PCD relates to the re-
sponse of a fungal pathogen to its host during infection, in
particular the events that accompany its clearance by the host
immune system (plant or animal). C. albicans infections are
controlled in immuno-competent individuals through the activityof both the innate and adaptive immune system; indeed defects in
the innate immune system are often responsible for predisposing
patients to disseminated disease. Macrophages and neutrophils
provide some of the primary lines of defence, consequently their
interaction with C. albicans cells has been the subject of a large
number of studies (see review in [166]). It is apparent that the
interaction results in a major re-organization or re-programming
of the transcriptional activity of both the host [167–169] and
fungal cells [170,171]. Recently Fernandez-Arenas et al. [172]
produced a model, based upon combined proteome and
transcriptome data obtained from C. albicans cells ingested by
RAW264.7 macrophages, indicating that the changes observed in
the actin cytoskeleton and mitochondrial functioning could be
associated with the onset of two distinct pathways of killing;
autophagic death or apoptosis. Clearly, further work needs to be
undertaken to unravel the nature of the killing mediated by
immune cells, but the information obtained could prove to be very
useful in designing therapies that manipulate the delicate balance
between a pathogen and its host.
13. Conclusion
This review has examinedwhat little we do knowabout the cell
biology of death responses in pathogenic fungi and shows how
a combination of cell biological approaches, functional genetic
analyses, genetic screens and global profiling technologies may
just begin to unravel this important, but neglected, aspect of fungal
growth and development. Furthermore, the existence of a number
of discrete endogenous cell suicide pathways in fungi might be
usefully exploited in the search for and design of novel therapies
in the future.
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